Skip to main content
SpringerLink
Log in
Book cover

Early Markers in Parkinson’s and Alzheimer’s Diseases pp 79–92Cite as

Urinary dopamine sulfate conjugates in Parkinson’s disease

  • Chapter

Part of the book series: New Vistas in Drug Research ((DRUG RESEARCH,volume 1))

Summary

Dopamine-3-O-sulfate (DA-3-O-S) and dopamine-4-O-sulfate (DA-4-O-S) have been shown to be important end-products of L-dopa metabolism. Therefore, when measured in urine samples of patients with Parkinson’s disease (PD), they may give indications of disorders in the peripheral metabolism of catecholamines. In addition, information about the reliability of DA sulfation after L-dopa therapy may be of significance in assessing its role in the elimination of DA from the peripheral nervous system.

Although DA-3-O-S seems to be the predominant sulfo-conjugate in urine, it is neither changed in PD compared to controls with or without other neurological disorders nor in depression syndrome. By contrast, DA4-O-S is significantly decreased in de novo PD patients. However, a similar reduction is notable in cases of other neurological disorders. In depressed patients, the loss of this compound is less pronounced as compared to de novo PD patients. Treatment with combined L-dopa therapy increases primarily DA-3-O-S, while changes in DA-4-O-S are only marginal.

It can be concluded that urinary DA-3-O-S cannot be used as a marker for PD, while DA-4-O-S is significantly reduced in a variety of neurological disorders and, in particular, in PD. Further studies are necessary to elucidate its role as possible peripheral marker to distinguish preclinical PD and depression syndrome.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Arakawa Y, Imai K, Tamura Z (1979) High-performance liquid chromatographic determination of dopamine sulfoconjugates in urine after L-dopa administration. J Chromatogr 162: 311–318

    Article  PubMed  CAS  Google Scholar 

  • Bacopoulos NG, Hattox SE, Roth RH (1979) 3,4-Dihydroxyphenylacetic acid and homovanillic acid in rat plasma: possible indicators of central dopaminergic activity. Eur J Pharmacol 56: 225–236

    Article  PubMed  CAS  Google Scholar 

  • Barbeau A (1961) Biochemistry of Parkinson’s disease. Excerpta Medica, ICS 38: 152–153

    Google Scholar 

  • Barbeau A (1969) Parkinson’s disease as a systemic disorder. In: Gillingham FJ, Sonaldson ML (eds) 3rd Symposium on Parkinson’s disease. Edinburgh, Livingstone, pp 66–73

    Google Scholar 

  • Barbeau A (1975) Pathophysiology of the oscillations in performance after long-term therapy with L-dopa. In: Birkmayer W, Hornykiewicz O (eds) Advances in parkinsonism. Editions Roche, Basel, pp 424–434

    Google Scholar 

  • Birkmayer W, Neumayer E (1972) Die moderne medikamentöse Behandlung des Parkinsonismus. Z Neurol 202: 257–280

    Article  PubMed  CAS  Google Scholar 

  • Bronaugh RL, Mattox SE, Hoehn MM, Murphy RC, Rutledge CO (1975) The separation and identification of dopamine 3-O-sulfate and dopamine 4-O-sulfate in urine of parkinsonian patients. J Pharmacol Exp Ther 195: 441–452

    PubMed  CAS  Google Scholar 

  • Buu NT (1985) Dopamine sulfoconjugation in the rat brain: regulation by monoamine oxidase. J Neurochem 45: 470–476

    Article  PubMed  CAS  Google Scholar 

  • Buu NT, Duhaime J, Savard C, Truong L, Kuchel O (1981) Presence of conjugated catecholamines in rat brain: a new method of analysis of catecholamine sulfates. J Neurochem 36 (2): 769–772

    Article  PubMed  CAS  Google Scholar 

  • Carmichael SW, Wilson RJ, Brimijoin WS, et al (1988) Decreased catecholamine levels in the adrenal medulla of patients with Parkinson’s disease. N Engl J Med 319: 254–256

    Google Scholar 

  • Corneille L, Lachance S, Demassieux S, Carrière S (1983) Turnover of free and conjugated serum catecholamines during haemodialysis. Clin Invest Med 6: 11–17

    PubMed  CAS  Google Scholar 

  • Demassieux S, Bordeleau L, Gravel D, Carrière S (1987) Catecholamine sulfates: end-products or metabolic intermediates? Life Sci 40: 183–191

    Article  PubMed  CAS  Google Scholar 

  • Elchisak MA (1983a) Determination of conjugated compounds by liquid chromatography with electrochemical detection using postcolumn hydrolysis. J Chromatogr 255: 475–482

    Article  CAS  Google Scholar 

  • Elchisak MA (1983b) Determination of dopamine-O-sulfate and norepinephrine-O-sulfate isomers and serotonine-O-sulfate by high-performance liquid chromatography using dual-electrode electrochemical detection. J Chromatogr 264: 119–127

    Article  CAS  Google Scholar 

  • Elchisak MA (1987) Analytical techniques for the determination of phenolic amine neurotransmitter conjugates. Life Sci 41: 913–916

    Article  PubMed  CAS  Google Scholar 

  • Elchisak MA, Carlson JN (1982) Method for analysis of dopamine sulfate isomers by high-performance liquid chromatography. Life Sci 30: 2325–2336

    Article  PubMed  CAS  Google Scholar 

  • Elsworth JD, Leahy DJ, Roth RH, Redmond jr DE (1986) Homovanillic acid concentrations in brain, CSF and plasma as indicators of central dopamine function in primates. J Neural Transm 68: 51–62

    Article  Google Scholar 

  • Foldes A, Meek JL (1974) Occurrence and localisation of brain phenosulfotransferase. J Neurochem 23: 303–307

    Article  PubMed  CAS  Google Scholar 

  • Glover V, Lees AJ, Ward C, Stern GM, Sandler M (1983) Platelet phenosulfotransferase activity in Parkinson’s disease. J Neural Transm 57: 95–102

    Article  PubMed  CAS  Google Scholar 

  • Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427–442

    PubMed  CAS  Google Scholar 

  • Jellinger K (1989) Pathology of Parkinson’s syndrome. In: Caine DB (ed) Handbook of experimental pharmacology, vol 88. Springer, Berlin Heidelberg New York, pp 47–112

    Google Scholar 

  • Jenner WN, Rose FA (1973) Studies on the sulphation of 3,4-dihydroxyphenylethylamine (dopamine) and related compounds by rat tissues. Biochem J 135: 109–114

    PubMed  CAS  Google Scholar 

  • Kienzl E, Eichinger K (1988) Preparation of dopamine 3-O-sulfate and dopamine 4-O-sulfate as reference substances and high-performance liquid chromatographic trace determination. J Chromatogr 430: 263–269

    Article  PubMed  CAS  Google Scholar 

  • Krijgsheld KR, Scholtens E, Mulder GJ (1982) The dependence of the rate of sulfate conjugation on the plasma concentration of inorganic sulfate in the rat in vivo. Biochem Pharmacol 31: 3997–4000

    Article  PubMed  CAS  Google Scholar 

  • Kuchel O, Hausser C, Buu NT, Tenneson S (1985) CSF sulfoconjugated catecholamines in man: their relationship with plasma catecholamines. J Neural Transm 62: 91–97

    Article  PubMed  CAS  Google Scholar 

  • Lackovic Z, Relja M, Neff NH (1982) Catabolism of endogenous dopamine in peripheral tissues: is there an independent role for dopamine in peripheral neurotransmission? J Neurochem 38: 1453–1458

    Article  PubMed  CAS  Google Scholar 

  • Renskers KJ, Feor KD, Roth JA (1980) Sulfation of dopamine and other biogenic amines by human brain sulfotransferase. J Neurochem 34: 1362–1368

    Article  PubMed  CAS  Google Scholar 

  • Riederer P, Rausch WD, Birkmayer W, Jellinger K, Seemann D (1978) CNS modulation of adrenal tyrosine hydroxylase in Parkinson’s disease and metabolic encephalopathies. J Neural Transm [Suppl] 141: 121–131

    Google Scholar 

  • Rivett AJ, Eddy BJ, Roth JA (1982) Contribution of sulfate conjugation, deamination and O-methylation to metabolism of dopamine and nor-epinephrine in human brain. J Neurochem 39: 1009–1016

    Article  PubMed  CAS  Google Scholar 

  • Rivett AJ, Francis A, Whittemore R, Roth JA (1984) Sulfate conjugation of dopamine in rat brain: regional distribution of activity and evidence for neuronal localisation. J Neurochem 42: 1444–1448

    Article  PubMed  CAS  Google Scholar 

  • Rutledge CO, Hoehn MM (1973) Sulfate conjugation and L-dopa treatment of parkinsonian patients. Nature 244: 447–450

    Article  PubMed  CAS  Google Scholar 

  • Scott MC, Elchisak MA (1983) Cardiovascular effects of dopamine sulfate in anesthetized dogs. Fed Proc 42: 13–63

    Google Scholar 

  • Scott MC, Elchisak MA (1987) Direct measurement of dopamine-O-sulfate in plasma and cerebrospinal fluid. J Chromatogr 413: 17–23

    Article  PubMed  CAS  Google Scholar 

  • Sullivan JM, Nakano KK, Tyler HR (1973) Plasma renin activity during levodopa therapy. Significance of long-and short-term treatment. J Am Med Assoc 224: 1726–1727

    Article  CAS  Google Scholar 

  • Tyce GM, Rorie DK (1982) Conjugated dopamine in superfusates of slices of rat striatum. J Neurochem 39: 1333–1339

    Article  PubMed  CAS  Google Scholar 

  • Tyce GM, Messick JM, Yaksh TL, Byer DE, Danielson DR, Rorie DK (1986) Amine sulfate formation in the central nervous system. Fed Proc 45 (8): 2247–2253

    PubMed  CAS  Google Scholar 

  • Van Loon GR (1980) Abnormal catecholamine mechanisms in hypothalamic-pituitary disorders. Metabolism 29 [Suppl] 1: 1198–1202

    Article  PubMed  Google Scholar 

  • Van Loon GR (1983) Plasma dopamine: regulation and significance. Fed Proc 42: 3012–3018

    PubMed  Google Scholar 

  • Van Loon GR, Sole MJ, Bain J (1979) Effects of bromocriptine on plasma catecholamines in normal men. Neuroendocrinology 28: 425–434

    Article  PubMed  Google Scholar 

  • Weinshilboum RM (1986) Phenol sulfotransferase in humans: properties, regulation and function. Fed Proc 45: 2223–2228

    PubMed  CAS  Google Scholar 

  • Westerink BHC, ten Kate N (1986) 24 h excretion patterns of free, conjugated and methylated catecholamines in man. J Clin Chem Clin Biochem 24: 513–519

    PubMed  CAS  Google Scholar 

  • Yamamoto T, Yamatodani A, Nishimura AM (1985) Determination of dopamine-3- and -4-O-sulfate in human plasma and urine by anion-exchange high-performance liquid chromatography with fluorimetric detection. J Chromatogr 342: 261–267

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ludwig-Boltzmann-Institute of Clinical Neurobiology, Lainz-Hospital, Vienna, Austria

    E. Kienzl & K. Jellinger

  2. Division of Chromatography and Spectroscopy, Institute of Organic Chemistry, Technical University, Vienna, Austria

    K. Eichinger

  3. Department of Neurology, University of Würzburg, Germany

    W. Kuhn

  4. Wohlfahrt, Parkinson Clinic, Federal Republic of Germany

    G. Fuchs

  5. Department of Neurology, Lainz Geriatric Hospital, Vienna, Austria

    W. Danielczyk

  6. Department of Neurochemistry, Institute of Physiology II, University of Marburg, Germany

    W. Wesemann

  7. Clinical Neurochemistry, Department of Psychiatry, University of Würzburg School of Medicine, Federal Republic of Germany

    P. Riederer

Authors
  1. E. Kienzl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Eichinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Jellinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. Kuhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Fuchs
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. W. Danielczyk
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W. Wesemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P. Riederer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Farmitalia Carlo Erba, R & D, Via Imbonati 24, I-20159, Milan, Italy

    Philippe Dostert , Margherita Strolin Benedetti  & Romeo Roncucci ,  & 

  2. Clinical Neurochemistry, Department of Psychiatry, University of Würzburg, Füchsleinstrasse 15, D-W-8700, Würzburg, Federal Republic of Germany

    Peter Riederer

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag/Wien

About this chapter

Cite this chapter

Kienzl, E. et al. (1990). Urinary dopamine sulfate conjugates in Parkinson’s disease. In: Dostert, P., Riederer, P., Strolin Benedetti, M., Roncucci, R. (eds) Early Markers in Parkinson’s and Alzheimer’s Diseases. New Vistas in Drug Research, vol 1. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9098-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-9098-2_10

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-9100-2

  • Online ISBN: 978-3-7091-9098-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation